Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Jean-Philippe

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Vaccine|July 27, 2011
Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunizationShabir A Madhi, Avy Violari, Keith P Klugman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 4, 2020
Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant WomenGrace Montepiedra, Soyeon Kim, Adriana Weinberg, et al.
Clinical and Vaccine Immunology : CVI|April 19, 2013
Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youthStephen A Spector, Min Qin, Jorge Lujan-Zilbermann, et al.
Vaccine|December 12, 2012
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infantsShabir A Madhi, Alane Izu, Avye Violari, et al.
The Pediatric Infectious Disease Journal|December 25, 2008
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patientsJennifer R King, Edward P Acosta, Ram Yogev, et al.
The Journal of Infectious Diseases|June 30, 2010
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infantsShabir A Madhi, Peter Adrian, Mark F Cotton, et al.
The Pediatric Infectious Disease Journal|May 18, 2016
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young AdultsMarc Foca, Ram Yogev, Andrew Wiznia, et al.
The Journal of Infectious Diseases|August 30, 2008
Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapyMona Rigaud, William Borkowsky, Petronella Muresan, et al.
The Pediatric Infectious Disease Journal|September 2, 2016
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young AdultsTim R Cressey, Rohan Hazra, Andrew Wiznia, et al.
Journal of the Pediatric Infectious Diseases Society|May 21, 2016
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young AdultsKajal B Larson, Tim R Cressey, Ram Yogev, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Vaccine|July 27, 2011
Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunizationShabir A Madhi, Avy Violari, Keith P Klugman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 4, 2020
Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant WomenGrace Montepiedra, Soyeon Kim, Adriana Weinberg, et al.
Clinical and Vaccine Immunology : CVI|April 19, 2013
Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youthStephen A Spector, Min Qin, Jorge Lujan-Zilbermann, et al.
Vaccine|December 12, 2012
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infantsShabir A Madhi, Alane Izu, Avye Violari, et al.
The Pediatric Infectious Disease Journal|December 25, 2008
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patientsJennifer R King, Edward P Acosta, Ram Yogev, et al.
The Journal of Infectious Diseases|June 30, 2010
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infantsShabir A Madhi, Peter Adrian, Mark F Cotton, et al.
The Pediatric Infectious Disease Journal|May 18, 2016
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young AdultsMarc Foca, Ram Yogev, Andrew Wiznia, et al.
The Journal of Infectious Diseases|August 30, 2008
Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapyMona Rigaud, William Borkowsky, Petronella Muresan, et al.
The Pediatric Infectious Disease Journal|September 2, 2016
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young AdultsTim R Cressey, Rohan Hazra, Andrew Wiznia, et al.
Journal of the Pediatric Infectious Diseases Society|May 21, 2016
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young AdultsKajal B Larson, Tim R Cressey, Ram Yogev, et al.
Pageof 9